Dec 15, 2020 / 04:00PM GMT
Operator
Thank you for standing by, and welcome to the Gossamer Bio Investor Day. (Operator Instructions) I would now like to hand the conference over to your speaker today, Faheem Hasnain. Please go ahead.
Faheem Hasnain - Gossamer Bio, Inc. - Co-Founder, CEO, President & Chairman
Good morning, everybody, and thanks so much for joining us today on the Gossamer Bio GB002 investor webcast. To introduce myself, my name is Faheem Hasnain. I'm the Co-Founder, Chairman and CEO of Gossamer Bio. We're a San Diego based company, focused on immunology, inflammation and oncology. We at Gossamer Bio are very excited to host this webcast and discuss our inhaled PDGFR inhibitor, GB002, which has entered a Phase II clinical trial for the treatment of pulmonary arterial hypertension. We put together an agenda for you today that we hope will be informative for everyone participating, including a discussion with 2 well-known PAH key opinion leaders.
Our first key opinion leader is Dr. Lewis Rubin, an Emeritus Professor at UC San Diego School of Medicine. Dr. Rubin was also
Gossamer Bio, Inc. - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
